HF
HRTX icon

HRT Financial’s Heron Therapeutics HRTX Stock Holding History

HRT Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,231
Closed -$64K – 3022
2025
Q1 		$64K Buy
+29,231
New +$56.7K ﹤0.01% 2212
2024
Q4 		– Sell
-426,817
Closed -$849K – 2747
2024
Q3 		$849K Buy
+426,817
New +$1.02M ﹤0.01% 1326
2024
Q1 		– Sell
-199,908
Closed -$339K – 2632
2023
Q4 		$339K Buy
+199,908
New +$220K ﹤0.01% 1566
2023
Q2 		– Sell
-547,365
Closed -$826K – 2799
2023
Q1 		$826K Buy
547,365
+107,981
+25% +$270K 0.01% 1050
2022
Q4 		$1.1M Buy
439,384
+58,943
+15% +$190K 0.02% 900
2022
Q3 		$1.6M Buy
+380,441
New +$1.49M 0.02% 691
2022
Q1 		– Sell
-37,662
Closed -$343K – 3409
2021
Q4 		$343K Buy
+37,662
New +$385K ﹤0.01% 2172

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HRT Financial's HRTX Position: Q2 2025 in Review

HRT Financial sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 29,231 shares — an estimated $64K sold.

HRT Financial first reported a position in HRTX in Q4 2021 and held it in 7 quarters. The position peaked at $1.6M in Q3 2022. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • HRT Financial reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 29,231 Heron Therapeutics shares in Q2 2025, an estimated $64K.
  • HRT Financial first reported a position in Heron Therapeutics in Q4 2021 and held it in 7 quarters.
  • HRT Financial's Heron Therapeutics position peaked at $1.6M in Q3 2022.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.